Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
The company is moving towards complex and more differentiated products
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Platina 250, 300 & 350 Lamitubes have been recognized by the Association of Plastic Recyclers (APR), USA as meeting or exceeding the strict APR HDPE critical guidance criteria on recyclability
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
The initiative will engage adolescents and youth of India in decisions about their reproductive health
It was recognized for its holistic initiatives designed to improve the quality of life and standards of care for patients
Subscribe To Our Newsletter & Stay Updated
